Literature DB >> 6836913

Glycosylation and intracellular transport of spleen focus-forming virus glycoproteins.

R V Srinivas, R W Compans.   

Abstract

We have investigated the pattern of glycosylation of the membrane glycoproteins encoded by a polycythemic strain of spleen focus-forming virus (SFFV). These include a major species designated gp52 and its processed form which is designated gp65. The SFFV glycoproteins were found to be predominantly intracellular, although a portion of gp65 is expressed on the cell surface. gp65 was observed to be highly sialylated and resistant to digestion with endoglycosidase-H (endo-H). In contrast, gp52 was endo-H sensitive and the polyacrylamide gel electrophoresis profile of the endo-H digests suggested the presence of four glycosylation sites. Analysis of tryptic glycopeptides from gp52 by reverse-phase high-performance liquid chromatography also suggested the presence of four glycosylation sites. Glycopeptide analysis of Pronase digests of gp52 revealed two major size classes with molecular weights of 2200 and 1500, which correspond to two of the four oligosaccharide size classes reported previously for MuLV gp70's (M.C. Kemp, N.G. Famulari, P.V. O'Donnell, and R.W. Compans, 1980, J. Virol. 34, 154). Both glycopeptide size classes were sensitive to digestion with endo-H. The glycopeptide profile of gp65 was found to be very heterogeneous and the predominant form was a 2900-dalton size class. In addition a fucosyl glycopeptide of 2500 daltons was observed in gp65, but not in F-MuLV or F-MCF glycoproteins. In the presence of the sodium ionophore monensin, the processing of gp52 to gp65 was inhibited. Instead a smaller protein of about 60,000 daltons was observed, which did not arrive at the cell surface, a situation analogous to the processing and post-translational modification reported for gp52 from anemic isolates of SFFV (S.K. Ruscetti, J.A. Field, and E.M. Scolnick, 1981, Nature (London) 294, 663).

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6836913     DOI: 10.1016/0042-6822(83)90201-5

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  7 in total

1.  A deletion in the Friend spleen focus-forming virus env gene is necessary for its product (gp55) to be leukemogenic.

Authors:  N Watanabe; M Nishi; Y Ikawa; H Amanuma
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

2.  Requirement of the single base insertion at the 3' end of the env-related gene of Friend spleen focus-forming virus for pathogenic activity and its effect on localization of the glycoprotein product (gp55).

Authors:  H Amanuma; N Watanabe; M Nishi; Y Ikawa
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

3.  Sequences responsible for the altered erythropoietin responsiveness in spleen focus-forming virus strain SFFVP-infected cells are localized to a 678-base-pair region at the 3' end of the envelope gene.

Authors:  S W Chung; L Wolff; S Ruscetti
Journal:  J Virol       Date:  1987-05       Impact factor: 5.103

4.  Defective transport of hemagglutinin-neuraminidase glycoprotein of bovine parainfluenza-3 virus in interferon treated cell.

Authors:  P Panigrahi; S B Mohanty
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

5.  Sequence comparisons of the anemia- and polycythemia-inducing strains of Friend spleen focus-forming virus.

Authors:  L Wolff; J Kaminchik; W D Hankins; S K Ruscetti
Journal:  J Virol       Date:  1985-02       Impact factor: 5.103

6.  Leukemogenic membrane glycoprotein encoded by Friend spleen focus-forming virus: transport to cell surfaces and shedding are controlled by disulfide-bonded dimerization and by cleavage of a hydrophobic membrane anchor.

Authors:  B C Gliniak; D Kabat
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

7.  Biological and biochemical differences between variants of spleen focus-forming virus can be localized to a region containing the 3' end of the envelope gene.

Authors:  S Ruscetti; L Wolff
Journal:  J Virol       Date:  1985-12       Impact factor: 5.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.